HIV Medicine · 2000 · 11 citations · 16 references
PharmacyPharmacoeconomicsPharmacotherapyCost-benefit AnalysisCost-effectiveness AnalysisHealthcare EconomicsAntiretroviral TherapyCost-effectiveness ComparisonEconomic EvaluationHealthcare Cost AnalysisPharmaceutical EconomicsPharmacoeconomic EvaluationCohort Study InvestigationCost-effective Antiviral UseImmunosuppressed Patient ManagementInpatient Care CostsPharmaceutical Cost AnalysisPharmacy Cost-effectiveness AnalysisPotential Economic ImpactTreatment Cost Analysis
OBJECTIVE: To evaluate the clinical and economical impact of the introduction of HIV protease inhibitor (PI) therapy in the current clinical care of HIV-infected patients. METHODS: Cohort study with 155 HIV-infected patients with a full year of follow-up before and after the introduction of PI by June 1998. The setting was a large urban tertiary teaching hospital in Madrid, Spain. The main outcomes measures were clinical and immunological evolution, pharmacy, out-patient, emergency room and in-patient medical costs evaluated by diagnostic-related group classification, and the global economic costs of clinical care in HIV-infected patients (AIDS and non-AIDS). RESULTS: The cost of PI therapy was compensated fully by savings related to reduction of the number, length and severity of hospital admissions in AIDS cases. In contrast, more modest clinical effects with increased costs were observed in non-AIDS cases. Globally, there was an increase of about 20% in the total health-care costs of HIV-infected patients (P < 0.01). CONCLUSIONS: PI therapy is highly cost-effective in AIDS patients. Its value in less severely immunosuppressed patients requires further evaluation.
16
Case mix definition by diagnosis-related groups.
Robert B. Fetter, Yoonhee Shin, J. L. Freeman et al. · PubMed · 1980 · 854 citations
The Care of HIV-Infected Adults in the United States
Samuel A. Bozzette, Sandra H. Berry, Naihua Duan et al. · New England Journal of Medicine · 1998 · 525 citations